“Although global health was historically dominated by U.N. agencies and bilateral organizations, new partnerships with the private sector have emerged since the 1990s,” Jeffrey Sturchio, senior partner at Rabin Martin, and Adel Mahmoud, a professor at Princeton University, write in the Huffington Post’s “Impact” blog. “In part, global health’s private…
Private Sector Involvement
“India has denied claims that it has exported large quantities of counterfeit medication to Africa, after the Guardian published a front-page exposÃ© on the phenomenon,” the Guardian reports in a follow-up article. The original article “cited experts and NGO reports as saying that up to a third of anti-malarial drugs in Uganda and Tanzania might be fake or substandard, and the majority of them were manufactured in China and India,” the newspaper writes, adding, “The fake medications have led to deaths, prolonged illness and increased drug resistance in parts of east Africa, the article said.” According to the Guardian, “The Indian health ministry launched a huge campaign last month to check the quality of medication manufactured across the country.” In addition, “Chinese officials also denied the charges made in the report,” the newspaper notes, citing another article published on December 28 (Burke, 1/2).
Thai Health Advocates Work To Protect Special Provisions On Medicines Under E.U. Free Trade Agreement
Thailand and the European Union (E.U.) are expected to begin talks on a free trade agreement early this year, and Thai public health advocates have sent a letter to Joao Aguiar Machado, deputy director general for trade at the European Commission, “call[ing] for the bloc to respect global trade rules’ special provisions for developing countries,” Inter Press Service reports. “‘We are worried that the E.U. negotiators will force Thailand to accept new conditions on patents that would make access to new generic drugs more difficult,’ says Chalermsak Kittitrakul, campaign officer at the AIDS Access Foundation,” the news service writes, adding, “Thai health activists are hoping that their record of mounting successful campaigns against pharmaceutical giants — even from the United States — to ensure a thriving generic drugs market for patients in the country and across the region remains intact” (Macan-Markar, 12/29).
“The U.S. Food and Drug Administration [on Monday] approved Johnson & Johnson’s drug to treat a form of resistant tuberculosis that is uncommon in the U.S. but growing globally,” the Wall Street Journal reports. “The drug, Sirturo, will treat patients with multidrug-resistant tuberculosis, or MDR-TB, a possibly fatal disease that affects as many as 630,000 people worldwide who can’t be cured with existing therapies alone,” the newspaper notes (Walker/Tadena, 1/2).
The U.S. Food and Drug Administration’s approval of the tuberculosis (TB) drug Sirturo, also known as bedaquiline, “appears to be just the first step in an exciting renaissance for TB drug development,” Mark Harrington, executive director of Treatment Action Group (TAG), writes in the Bill & Melinda Gates Foundation’s “Impatient Optimists” blog. “Another new drug, delamanid, is currently in late clinical trials and has been submitted to the European Medicines Agency for review as a treatment for [multidrug-resistant (MDR)] TB,” he notes. Harrington concludes, “It’s an exciting time for TB treatment, but much more needs to be done and more resources are needed. We need to focus not only on the discovery and development of new drugs, but also on ensuring that news drugs are delivered to those who need them and in combinations that can prevent the emergence of new types of drug resistance” (12/28).
“Twenty years ago this month, the first text message was sent through the airwaves,” Sharon D’Agostino, vice president for worldwide corporate contributions and community relations at Johnson & Johnson, writes in the Bill & Melinda Gates Foundation’s “Impatient Optimists” blog, adding, “Since then, text messages have been used to communicate all sorts of information. Most inspiring to me is how the technology once used to send a holiday wish is transforming the way women and families receive the information they need to be healthier — no matter where in the world they are.” She discusses several initiatives working with mobile technologies to improve health education and access, and states, “The ubiquity of the mobile phone provides the perfect method to deliver critical health information, as more than a billion women in low- and middle-income countries have access to a mobile phone” (12/20).
Nick Chapman, a policy analyst at Policy Cures, writes in a guest post on the Global Health Technologies Coalition’s “Breakthroughs” blog about “the results of the latest G-FINDER survey on global funding of [research and development (R&D)] for neglected diseases.” He discusses several findings and trends from the report, including the impact of the global financial recession on R&D funding; the relatively stable level of U.S. funding; the concentration of pharmaceutical company funding to “a limited number of diseases with some commercial overlap, such as dengue fever, bacterial pneumonia and meningitis, and tuberculosis (TB)”; the shift away from product development funding from public funders; and the effect of these trends on product development partnerships (PDPs) (Lufkin, 12/19).
“Nigeria is one of only three countries — along with Afghanistan and Pakistan — that remains blighted by polio,” Aliko Dangote, founder and CEO of the Dangote Group and chair of the Dangote Foundation, writes in a Project Syndicate opinion piece. He notes Nigeria is “one of Africa’s most developed countries,” “the largest recipient of foreign direct investment in Africa,” home to “thriving Nigerian businesses,” and “will soon surpass South Africa to become Africaâ€™s largest economy.” However, “Nigerians cannot hope to lead Africa, economically or otherwise, while neglecting to eliminate preventable diseases like polio,” he writes.
Seattle Times Examines Partnership Between Hutchinson Cancer Research Center, Uganda Cancer Institute
The Seattle Times examines a partnership between the Fred Hutchinson Cancer Research Center and the Uganda Cancer Institute (UCI). In 2008, “the two institutes formally agreed to collaborate on clinical care and research projects, and more recently a major building project at Uganda’s only cancer-research center,” the newspaper writes. Corey Casper, director of the UCI/Fred Hutchinson Research Center Cancer Alliance, “says [the partnership] has the potential to demonstrate ‘that you can do first-rate research that can alter the impact of cancer care in the developing world, and that the craft of oncology can be practiced as well in Africa as it is in the developed world, just like it is with HIV,'” according to the Seattle Times (Silberner, 12/16).
Several blogs recently reported on issues discussed last week during a conference sponsored by Medecins Sans Frontieres (MSF), the Drugs for Neglected Diseases initiative (DNDi), and the Mount Sinai School of Medicine in New York, titled “Lives in the Balance: Delivering Medical Innovations for Neglected Patients and Populations.” The following is a list of those posts.